A “Thank You Gift” From Pres. Trump - Genius

The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…

Marcio Souza Biography and Net Worth

CEO of Praxis Precision Medicines

Marcio Souza has served as a director and our President and Chief Executive Officer since April 2020. Prior to joining us, Mr. Souza was at PTC Therapeutics, Inc., or PTC, where he served as its Chief Operating Officer from May 2017 to April 2020 and its Senior Vice President and Head of Product Strategy from July 2016 to May 2017. Prior to joining PTC, Mr. Souza served in positions of increasing responsibility at NPS Pharmaceuticals, Inc., Shire Human Genetic Therapies Inc. and Sanofi Genzyme Corporation. From May 2019 to May 2020, Mr. Souza also served on the board of directors of Clearpoint Neuro, Inc. (previously MRI Interventions, Inc.). Mr. Souza received a degree in pharmacy and biochemistry with a specialization in toxicology and clinical analysis from the University of São Paulo and an M.B.A. from Fundação Dom Cabral.

What is Marcio Souza's net worth?: The estimated net worth of Marcio Souza is at least $223,500.00 as of June 27th, 2023. Mr. Souza owns 3,000 shares of Praxis Precision Medicines stock worth more than $223,500 as of November 23rd. This net worth approximation does not reflect any other assets that Mr. Souza may own. Additionally, Mr. Souza receives a salary of $1,180,000.00 as CEO at Praxis Precision Medicines. Learn More about Marcio Souza's net worth.
How old is Marcio Souza?: Mr. Souza is currently 45 years old. There are 4 older executives and no younger executives at Praxis Precision Medicines. Learn More on Marcio Souza's age.
What is Marcio Souza's salary?: As the CEO of Praxis Precision Medicines, Inc., Mr. Souza earns $1,180,000.00 per year. Learn More on Marcio Souza's salary.
How do I contact Marcio Souza?: The corporate mailing address for Mr. Souza and other Praxis Precision Medicines executives is 101 MAIN STREET #1210, CAMBRIDGE MA, 02142. Praxis Precision Medicines can also be reached via phone at 617-300-8460 and via email at [email protected]. Learn More on Marcio Souza's contact information.
Has Marcio Souza been buying or selling shares of Praxis Precision Medicines?: Marcio Souza has not been actively trading shares of Praxis Precision Medicines in the last ninety days. Most recently, on Tuesday, June 27th, Marcio Souza bought 666 shares of Praxis Precision Medicines stock. The stock was acquired at an average cost of $15.90 per share, with a total value of $10,589.40. Following the completion of the transaction, the chief executive officer now directly owns 3,000 shares of the company's stock, valued at $47,700. Learn More on Marcio Souza's trading history.
Are insiders buying or selling shares of Praxis Precision Medicines?: In the last twelve months, insiders at the sold shares 2 times. They sold a total of 13,427 shares worth more than $1,085,042.44. The most recent insider tranaction occured on November, 14th when General Counsel Alex Nemiroff sold 8,239 shares worth more than $660,767.80. Insiders at Praxis Precision Medicines own 2.7% of the company. Learn More about insider trades at Praxis Precision Medicines.
Information on this page was last updated on 11/14/2024.

Marcio Souza Insider Trading History at Praxis Precision Medicines

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/27/2023	Buy	666	$15.90	$10,589.40	3,000
3/23/2023	Buy	2,333	$12.90	$30,095.70	15,086
6/8/2022	Buy	1,800	$27.75	$49,950.00	12,612
8/18/2021	Buy	636	$236.85	$150,636.60
11/10/2020	Buy	256	$391.20	$100,147.20	1,630

Marcio Souza Buying and Selling Activity at Praxis Precision Medicines

Praxis Precision Medicines Company Overview

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Today's Range

Now: $74.50

$71.27

$76.04

50 Day Range

MA: $68.42

$56.55

$84.83

2 Week Range

Now: $74.50

$14.77

$86.93

Volume

233,108 shs

Average Volume

357,042 shs

Market Capitalization

$1.39 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.67

A “Thank You Gift” From Pres. Trump - Genius

From Colonial Metals | Ad

Claim your FREE 2024 Gold Guide

Marcio Souza Biography and Net Worth

What is Marcio Souza's net worth?

How old is Marcio Souza?

What is Marcio Souza's salary?

How do I contact Marcio Souza?

Has Marcio Souza been buying or selling shares of Praxis Precision Medicines?

Are insiders buying or selling shares of Praxis Precision Medicines?